| P50 | author | Thomas F Baumert | Q88786090 |
| | Atsushi Ono | Q118189231 |
| P2093 | author name string | Yujin Hoshida | |
| | Frank Jühling | |
| P2860 | cites work | Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma | Q22305316 |
| | Virologic Tools for HCV Drug Resistance Testing | Q26774374 |
| | Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? | Q27025083 |
| | Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis | Q28076352 |
| | Hepatitis C | Q28084654 |
| | The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control | Q30245243 |
| | Access to treatment for hepatitis C virus infection: time to put patients first | Q30248987 |
| | The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine | Q30252122 |
| | Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts | Q31107310 |
| | Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma | Q33628443 |
| | Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. | Q34028307 |
| | Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C | Q34671935 |
| | Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma | Q35619104 |
| | Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function | Q35911913 |
| | Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008 | Q36100389 |
| | New perspectives for preventing hepatitis C virus liver graft infection | Q37015805 |
| | Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection | Q37029846 |
| | Global control of hepatitis C: where challenge meets opportunity | Q37077112 |
| | Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030 | Q37137944 |
| | Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy | Q37328172 |
| | Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection | Q37780324 |
| | Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia | Q38233245 |
| | Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition | Q38726399 |
| | Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens | Q38808740 |
| | A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. | Q38848401 |
| | Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies | Q38856649 |
| | Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection | Q39039478 |
| | Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios | Q39193224 |
| | Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada | Q39211151 |
| | Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon | Q39240225 |
| | Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. | Q39250270 |
| | Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications | Q39376677 |
| | Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). | Q39445534 |
| | Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population | Q39469623 |
| | Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. | Q39483711 |
| | Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. | Q39695580 |
| | Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. | Q39745561 |
| | Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy | Q39846654 |
| | Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy | Q39854779 |
| | Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals. | Q40414240 |
| | Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. | Q40446411 |
| | Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival | Q40522920 |
| | Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals | Q40528873 |
| | Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis | Q40557601 |
| | Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis | Q40621775 |
| | Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. | Q40627095 |
| | Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals | Q40634884 |
| | Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. | Q40645393 |
| | Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy | Q40722730 |
| | Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir | Q40735892 |
| | Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma | Q40782607 |
| | Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population | Q40810821 |
| | Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis | Q40826218 |
| | Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. | Q40903867 |
| | Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. | Q40904392 |
| | Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment | Q41082823 |
| | The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients | Q41654105 |
| | Restoration of HCV-specific CD8+ T cell function by interferon-free therapy | Q42211746 |
| | Curing chronic hepatitis C--the arc of a medical triumph | Q42225548 |
| | Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication | Q42232663 |
| | Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy | Q42250183 |
| | Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes | Q42250363 |
| | Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection | Q42978559 |
| | Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection | Q42998885 |
| | Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity | Q43034947 |
| | Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. | Q43036185 |
| | Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon | Q46381851 |
| | A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. | Q50551357 |
| | A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. | Q52713010 |
| | Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. | Q54505335 |
| | Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment | Q87700511 |
| | The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma | Q88126733 |
| | EASL Recommendations on Treatment of Hepatitis C 2016 | Q88412279 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| | hepatocellular carcinoma | Q1148337 |
| | liver neoplasm | Q18558073 |
| | antiviral agent | Q40207875 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 52 | |
| P577 | publication date | 2017-03-14 | |
| P1433 | published in | BMC Medicine | Q4835947 |
| P1476 | title | Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals | |
| P478 | volume | 15 | |